[Viva] Fwd: TreatmentUpdate 206

[Denise Wozniak]

---------- Forwarded message ----------
From: CATIE <mailer at catie.ca>
Date: Mon, Jan 19, 2015 at 7:38 PM
Subject: TreatmentUpdate 206
To: dbecker106 at gmail.com


     TreatmentUpdate 206
     [image: TreatmentUpdate Banner]        *TreatmentUpdate* 206
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-206?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=tu206>

*January 2015*

*HIV—Pregnancy-related issues
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-206/hiv-pregnancy-related-issues?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=tu206>*

U.S. analysis of the safety of ART during pregnancy
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-206/hiv-pregnancy-related-issues/us-analysis-safety-art-during-pregn?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=tu206>

Potent combination anti-HIV therapy (commonly called ART or HAART) has
produced tremendous benefits for HIV-positive people, improving their
survival and health. Faced with such promising prospects, some HIV-positive
people are starting families. Today, it is extremely rare for infants in
Canada to be born with HIV or to become infected after birth when
preventive measures are taken. The vast majority of analyses have been
reassuring about the general safety of ART on the fetus. However, signals
of a possibly increased risk for birth defects have emerged from some
analyses in the past decade.

Good news about HIV drug safety from an even larger study
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-206/hiv-pregnancy-related-issues/good-news-about-hiv-drug-safety-eve?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=tu206>

The largest database that has captured information on the safety of ART
used during pregnancy is the Antiviral Pregnancy Registry. Scientists with
the Registry have analysed information collected between 1989 and 2014.
Researchers with the Registry made the following statement: “For the
overall population exposed to antiretroviral drugs in this Registry, no
increases in risk of overall birth defects or specific defects have been
detected to date.”

Understanding the risks for hypospadias
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-206/hiv-pregnancy-related-issues/understanding-risks-hypospadias?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=tu206>

Some studies have found a possible link between the use of certain
medicines in pregnancy and a risk of male genital birth defects, or
hypospadias. In this article, we put the risk for hypospadias in context.

ART during pregnancy found safe for babies’ hearts
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-206/hiv-pregnancy-related-issues/art-during-pregnancy-found-safe-bab?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=tu206>

The use of potent combination anti-HIV therapy (commonly called ART or
HAART) along with other measures can significantly help pregnant
HIV-positive women give birth to healthy, HIV-negative babies. Researchers
are continuing to monitor the health of babies born to HIV-positive mothers
to assess the safety of ART. In one such study, researchers found no
evidence of toxicity to the heart in children born to HIV-positive mothers
who used ART during pregnancy.

General risk factors for premature births
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-206/hiv-pregnancy-related-issues/general-risk-factors-premature-birt?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=tu206>

One of the reports in this issue of *TreatmentUpdate* deals with a hormonal
issue that appears to cause some HIV-positive women to give birth
prematurely. Before delving into this report, we first provide some
background about prematurity.

Premature births, protease inhibitors and progesterone
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-206/hiv-pregnancy-related-issues/premature-births-protease-inhibitor?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=tu206>

In recent years, as treatment guidelines in high-income countries shift
toward encouraging all HIV-positive people, regardless of CD4+ count, to
initiate ART, and new drugs have become available, more research is needed
to help doctors better understand the safety of ART during pregnancy.
Researchers in Toronto have been investigating the potential impact on
pregnancy of protease inhibitors, a commonly prescribed class of anti-HIV
drugs for pregnant women in high-income countries.

Attitudes toward rapid HIV testing during labour
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-206/hiv-pregnancy-related-issues/attitudes-toward-rapid-hiv-testing-?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=tu206>

Hospitals have encountered visits from women very late in pregnancy or who
were in labour and who had no idea of their HIV status. In such cases, HIV
testing must be done with rapid testing to help doctors decide if measures
are necessary to protect the fetus during and after the birthing process.
In the summer of 2011, as part of a study, researchers at St. Michael’s
Hospital in Toronto surveyed 152 pregnant women about the acceptability and
attitudes that they have toward receiving the *possibility* of HIV testing
during labour.

Pregnancy-related resources
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-206/hiv-pregnancy-related-issues/pregnancy-related-resources?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=tu206>

If you are pregnant or want to have a baby and are concerned about having a
healthy baby, speak to your doctor and nurse, and consult this list of
resources.
         [image: Twitter] <http://twitter.com/#!/CATIEInfo>     [image:
Facebook] <http://www.facebook.com/pages/CATIEInfo/104321259649840>     [image:
youtube] <http://www.youtube.com/catieinfo>
    <http://www.catie.ca>

CATIE is Canada's source for up-to-date, unbiased information about HIV and
hepatitis C

*Tel: 1-800-263-1638 <1-800-263-1638>*

*www.catie.ca <http://www.catie.ca>*

If you wish to unsubscribe, please use this link
<http://www.catie.ca/en/about/media/subscriptions/unsubscribe>.

Permission to reproduce <http://www.catie.ca/en/permission-reproduce>
CATIE Privacy Statement <http://www.catie.ca/en/catie-privacy-statement>
Disclaimer

Decisions about particular medical treatments should always be made in
consultation with a qualified medical practitioner knowledgeable about HIV-
and hepatitis C-related illness and the treatments in question. More...
<http://www.catie.ca/en/disclaimer>
Third-Party Website Disclaimer

This e-Bulletin contains links to third party Websites ("Linked Sites").
The Linked Sites are not under the control of CATIE and CATIE is not
responsible for the contents of any Linked Site, including any link
contained in a Linked Site or any changes or updates to a Linked Site. The
Linked Sites may not be available in French or English. CATIE is providing
these links to you only as a convenience, and the inclusion of any link
does not imply endorsement by CATIE of the Linked Site or any association
with its operators. We do not guarantee the accuracy or completeness of any
information accessed through or published or provided by the Linked Site
and if you rely upon any such information, you do so entirely at your own
risk. You are responsible for viewing and abiding by the privacy statements
and terms of use posted at the Linked Sites. Any specific comments or
inquiries regarding the Linked Sites should be directed to the operator of
the Linked Site.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.resist.ca/pipermail/viva/attachments/20150120/0d186515/attachment-0001.html>